Jubilant Life Sciences on Tuesday reported a profit after tax of Rs.27 crore for the quarter ended December, mainly on account of robust sales.
The company’s income from operations during the same period was Rs.1,306 crore, growing over 19% from last year.
It had posted a net loss of Rs.78.39 crore for the corresponding a year ago, Jubilant Life Sciences said in a statement.
In the nine months from April 1, the company delivered a strong revenue growth of 22% with 26% growth in EBITDA (earnings before interest, taxes, depreciation and amortisation) over last year, driven by top line growth in the pharma segment.
Commenting on the performance, Shyam S Bhartia, CMD, and Hari S Bhartia, co-chairman and MD, Jubilant Life Sciences said, “Our strategy of enhancing presence in identified international markets is delivering results with 28% growth and high 73% contribution to revenue mix.
“We believe this momentum is sustainable due to strong product pipeline and order book position along with leveraging benefits from vertical integration.”